Marco A. Ciufolini

Prof. Marco A. Ciufolini


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2011 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
HLHuan Liang
Huan Liang
MCMarco A. Ciufolini
Marco A. Ciufolini

19 May 2009 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
DLDavid Lefranc
David Lefranc
MCMarco A. Ciufolini
Marco A. Ciufolini
Fifty years after the discovery of the thiopeptide antibiotic micrococcin P1, the constitutional and stereochemical uncertainties concerning its structure have been lifted with its total synthesis and absolute stereochemical assignment (see picture). magnified image

7 October 2010 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
HLHuan Liang
Huan Liang
MCMarco A. Ciufolini
Marco A. Ciufolini

15 March 2017 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
NJNikita Jain
Nikita Jain
SXSanjia Xu
Sanjia Xu
MCMarco A. Ciufolini
Marco A. Ciufolini

1 August 2021 in Small
Verified
Journal Article
Open access
PDF file
RMRoy van der Meel
Roy van der Meel
SCSam Chen
Sam Chen
JZJosh Zaifman
Josh Zaifman
JKJayesh A. Kulkarni
Jayesh A. Kulkarni
XZXu Ran S. Zhang
Xu Ran S. Zhang
YTYuen Yi C. Tam
Yuen Yi C. Tam
Successfully employing small interfering RNA (siRNA) therapeutics requires the use of nanotechnology for efficient intracellular delivery. Lipid nanoparticles (LNPs) have enabled the approval of various nucleic acid therapeutics. A major advantage of LNPs is the interchangeability of its building blocks and RNA payload, which allow it to be a highly modular system. In addition, drug derivatization approaches can be used to synthesize lipophilic small molecule prodrugs that stably incorporate in LNPs. This provides ample opportunities to develop combination therapies by co‐encapsulating multiple therapeutic agents in a single formulation. Here, it is described how the modular LNP platform is applied for combined gene silencing and chemotherapy to induce additive anticancer effects. It is shown that various lipophilic taxane prodrug derivatives and siRNA against the androgen receptor, a prostate cancer driver, can be efficiently and stably co‐encapsulated in LNPs without compromising physicochemical properties or gene‐silencing ability. Moreover, it is demonstrated that the combination therapy induces additive therapeutic effects in vitro. Using a double‐radiolabeling approach, the pharmacokinetic properties and biodistribution of LNPs and prodrugs following systemic administration in tumor‐bearing mice are quantitatively determined. These results indicate that co‐encapsulating siRNA and lipophilic prodrugs into LNPs is an attractive and straightforward plug‐and‐play approach for combination therapy development.

22 January 2010 in Natural Product Reports
Verified
Journal Article
Closed access
PDF file
MCMarco A. Ciufolini
Marco A. Ciufolini
DLDavid Lefranc
David Lefranc
Covering: 1948 to August 2009 Micrococcin P1, 1, is an antibiotic that exhibits noteworthy antibacterial, antiprotozoal, antimalarial, cytotoxic, and gene-modulating activities. This notwithstanding, its precise structure remained undefined until mid-2009, when our group carried out the total synthesis of a substance that proved to be spectroscopically and polarimetrically identical to the natural product. This work lifted all structural and stereochemical ambiguities that have surrounded micrococcin since its discovery. Of course, knowledge of the precise structure of the molecule is essential in understanding intimate details of its mode of action and in charting possible medicinal chemistry activity. This review summarizes present knowledge about the sources, properties, and chemical synthesis of micrococcin P1.